novo nordisk cuts prices for its glp-1 drugs. WEIGHT-LOSS DRUG ON THE DECLINE! This downward trend isn’t limited to a single medication. As competition increases and more treatment options enter the market, the overall cost of medically Imagine being told you found

Janus, C

There is no need for a formal transfer of records, though knowing your current dose and any side effects you have experienced helps the new provider make informed decisions

Sources of uncertainty originate from the panoply of glycemic targets, the complexity of drug therapy, the choice of the first drug, the ideal sequence of drugs after the first drug failure, the possible harms of anti-hyperglycemic drugs, the outcomes of treatment (surrogate versus clinical) and the hierarchy of risk factors to treat for preventing the vascular complications

Obesity in adults

is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire obesity-drug developer Metsera

Whats more, a recent retrospective, multicenter cohort study denied higher occurrence of nonarteritic anterior ischemic optic neuropathy (NAION) in GLP-1RAs users and suggested that its potential benefits for blood glucose control and cardiovascular health likely outweigh its risks (Chou et al., 2025), despite that a few research have reported association between semaglutide prescription and a higher risk of NAION(61)